Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US9468605B2 · kind B2 · utility
1Cited by
7References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2014 |
| Grant date | Oct 18, 2016 |
| Priority date | — |
| Expiry date | Jun 16, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4035
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-α production in mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.